A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancerElena Garralda, Gerald S. Falchook, J. Palcza et al.|ESMO Open|2022Cited by 87